Neurology Specific Literature Search   
 
[home][thesaurus]
    

Differential
(Click to cross reference)
acute disseminated encephalomyelitis
adverse drug reaction
anti MAG antibodies
aphasia
atypical
bradycardia
brain biopsy
brain biopsy, false negative
brain biopsy, indication
CAT scan
CAT scan, abnormal
CAT scan, demyelinating disease
CAT scan, mass effect on
CAT scan, ring sign
cerebral edema
cerebrospinal fluid, abnormal
complications
cyst, cortical parenchyma
delay in diagnosis
demyelinating disease
differential diagnosis
drug induced neurologic disorders
encephalitis
encephalomyelitis, postinfectious
fingolimod
gadolinium
glioma
headache
hemiparesis
iatrogenic neurologic disorders
immunomodulation
immunosuppression
leukopenia
lymphoma
lymphoma involving CNS
lymphoma, primary of CNS
macular edema
misdiagnosis
MRI
MRI, abnormal
MRI, CAT scan compared to
MRI, contrast enhanced
MRI, demyelinating disease
MRI, diffusion weighted
MRI, mass effect on
MRI, ring sign
MRI, ring sign, open
MRS
multiple sclerosis
multiple sclerosis, diagnosis of
multiple sclerosis, differential diagnosis of
multiple sclerosis, misdiagnosis
multiple sclerosis, treatment of
multiple sclerosis, tumefactive
neoplasm, intracranial
neoplasm, metastatic to CNS
neoplasm, primary intracerebral
neoplasm, primary of CNS
neurologic disease, diagnoses of
neuromyelitis optica (Devic's disease)
neuromyelitis optica spectrum disorder
plasmapheresis
prognosis
pseudotumor
recurrent
review article
seizure
single photon emission computed tomography
single photon emission computed tomography, thallium
steroid therapy, CNS treatment and complications with
treatment of neurologic disorder
tumefactive lesion
vaccination, neurologic complications with
Virchow-Robin spaces, dilated
workup
Showing articles 250 to 300 of 1333 << Previous Next >>

Tempo of Disease. In Merritts Neurology. Signs and symptoms in neurologic diagnosis: Approach to the patient
, Rowland, L.P.,et al, 2009

Relapse Management in Multiple Sclerosis
The Neurologist 15:1-5, Thrower,B.W., 2009

Picturing Multiple Sclerosis: Conventional and Diffusion Tensor Imaging
Semin Neurol 28:453-466, Fox,R.J., 2008

Risk Factors of Cerebral Vein and Sinus Thrombosis
Front Neurol Neurosci 23:23-54, de Freitas, G.R. & Bogousslavsky, J., 2008

An Approach to the Diagnosis of Acute Transverse Myelitis
Semin Neurol 28:105-120, Jacob, A.,et al, 2008

Bal�s Disease Showing Benign Clinical Course and Co-Existence with Multiple Sclerosis-Like Lesions in Chinese
Multiple Sclerosis 14:418-424, Wang,C.,et al, 2008

What Are the Prospects of Stem Cell Therapy for Neurology?
BMJ 337:1325-1327, Chandran,S., 2008

Natalizumab Use in Pediatric Multiple Sclerosis
Arch Neurol 65:1655-1658, Huppke,P.,et al, 2008

4-Aminopyridine Toxicity with Unintentional Overdose in Four Patients with Multiple Sclerosis
Neurol 71:1833-1834, Burton,J.M.,et al, 2008

Non-Communicating Syringomyelia: A Feature of Spinal Cord Involvement in Multiple Sclerosis
Brain 131:1776-1782, Weier,K.,et al, 2008

Melanoma Complicating Treatment with Natalizumab for Multiple Sclerosis
NEJM 358:647-648, Mullen,J.T.,et al, 2008

Mitoxantrone as Induction Treatment in aggressive Relapsing Remitting Multiple Sclerosis: Treatment Response Factors in a 5 Year Follow-up Observational Study of 100 Consecutive Patients
JNNP 79:52-56, Le Page,E.,et al, 2008

Unexpected Multiple Sclerosis: Follow-Up of 30 Patients With Magnetic Resonance Imaging and Clinical Conversion Profile
JNNP 79:195-198,112, Lebrun,C.,et al, 2008

B-Cell Depletion with Rituximab in Relapsing-Remitting Multiple Sclerosis
NEJM 358:676-688, Hauser,S.L.,et al, 2008

Postwithdrawal Rebound Increase in T2 Lesional Activity in Natalizumab-Treated MS Patients
Neurol 70:1150-1151,1073, Vellinga,M.M.,et al, 2008

Do Oligoclonal Bands Add Information to MRI in First Attacks of Multiple Sclerosis?
Neurol 70:1079-1083,1059, Tintore,M.,et al, 2008

Interferon �-Associated Retinopathy in Patients Treated for Multiple Sclerosis
Neurol 70:1153-1155, Folden,D.V.,et al, 2008

Mlutiple Sclerosis Risk After Optic Neuritis: Final Optic Neuritis Treatment Trial Follow-Up
Arch Neurol 65:727-732, The Optic Neuritis Study Group, 2008

Effect of Laquinimod on MRI-Monitored Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IIb Study
Lancet 371:2085-2092,2059, Comi,G.,etc., 2008

Reduction of Disease Activity and Disability With High-Dose Cyclophosphamide in Patients With Aggressive Multiple Sclerosis
Arch Neurol 65:1044-1051, Krishnan,C.,et al., 2008

Rapidly Progressive Dementia
Ann Neurol 64:97-108, Geschwind,M.D.,et al., 2008

Four New Cases of Therapy-Related Acute Promyelocytic Leukemia After Mitoxantrone
Neurol 71:457-458, Bosca,I.,et al., 2008

Anti-Tumor Necrosis Factor Alpha-Associated Multiple Sclerosis
AJNR 26:1548-1550, Titelbaum,D.S.,et al., 2008

Multiple Sclerosis and Cannabis: A Cognitive and Psychiatric Study
Neurol 71:164-169, Ghaffar,O. &Feinstein,A., 2008

Assessment: The Use of Natalizumab (Tysabri) for the Treatment of Multiple Sclerosis (An Evidence-Based Review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 71:766-773, Goodin,D.S.,et al., 2008

Monoclonal Antibody Therapies and Neurologic Disorders
Arch Neurol 65:1162-1165, Novack,J.C.,et al., 2008

Glatiramer Acetate--Associated, CD30+, Primary, Cutaneous, Anaplastic Large-Cell Lymphoma
Arch Neurol 65:1378-1379, Madray,M.M.,et al, 2008

Gray Matter Atrophy in Multiple Sclerosis: A Longitudinal Study
Ann Neurol 64:255-265,230, Fisher,E.,et al, 2008

Efficacy and Safety of Oral Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase LLB Study
Lancet 372:1463-1472, Kappos,L.,et al, 2008

Multiple Sclerosis
Lancet 372:1502-1517, Compston,A. &Coles,A., 2008

Combining Beta Interferon and Atorvastatin May Increase Disease Activity in Multiple Sclerosis
Neurol 71:1390-1395,1386, Birnbaum,G.,et al, 2008

Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
NEJM 359:1786-1801,1838, The CAMMS223 Trial Investigators, 2008

Multiple Sclerosis After Infectious Mononucleosis
Arch Neurol 64:72-75, Nielsen,T.R.,et al, 2007

Longitudinal Follow-Up of "Benign" Multiple Sclerosis at 20 Years
Neurol 68:496-500,480, Sayao,A-L.,et al, 2007

Gray Matter Involvement in Multiple Sclerosis
Neurol 68:634-642, Pirko,I.,et al, 2007

Sexual Function in Men and Women With Neurological Disorders
Lancet 369:512-525, Rees,P.M.,et al, 2007

Randomized, Double-Blind, Dose-Comparison Study of Glatiramer Acetate in Relapsing-Remitting MS
Neurol 68:939-944, Cohen,J.A.,et a, 2007

Balos Concentric Sclerosis Presenting as a Stroke-Like Syndrome
Nat Clin Pract Neurol 3:349-354, Mowry,E.M.,et al, 2007

Reactivation of JC Virus and Development of PML in Patients With Multiple Sclerosis
Neurol 68:985-990, Khalili,K.,et al, 2007

Neutralizing Antibodies to Interferon Beta: Assessment of Their Clinical and Radiographic Impact: An Evidence Report
Neurol 68:977-984, Goodin,D.S.,et al, 2007

Natalizumab Reduces Visual Loss in Patients with Relapsing Multiple Sclerosis
Neurol 68:1299-1302, Balcer,L.J.,et al, 2007

Mitoxantrone for Multiple Sclerosis Causing Acute Lymphoblastic Leukemia
Neurol 68:1630-1631, Cartwright,M.S.,et al, 2007

Quantifying the Risks and Benefits of Natalizumab in Relapsing Multiple Sclerosis
Neurol 68:1524-1528, Dorsey,E.R.,et al, 2007

MRI Outcomes in a Placebo-Controlled Trial of Natalizumab in Relapsing MS
Neurol 68:1390-1401, Miller,D.H.,et al, 2007

Natural History of Multiple Sclerosis with Childhood Onset
NEJM 356:2603-2613, Renoux,C.,et al, 2007

Natalizumab for Multiple Sclerosis
NEJM 356:2622-2629, Ransohoff,R.M., 2007

Neuropsychiatric Syndromes Associated With Multiple Sclerosis
J Neurol 254:II/73-II/76, Feinstein,A., 2007

Natalizumab (Tysabri) Treatment for Relapsing Multiple Sclerosis
The Neurologist 13:182-187, Johnson,K.P., 2007

Effect of Early Verus Delayed Interferon Beta-1b Treatment on Disability After a First Clinical Event Suggestive of Multiple Sclerosis: A 3-Year Follow-Up Analysis of the BENEFIT Study
Lancet 370:389-397, Kappos,L.,et al, 2007

What Do We Really See When We Look at Magnetic Resonance Images?
Ann Neurol 62:207-208, Filippi,M. &Hartung,H.-P., 2007



Showing articles 250 to 300 of 1333 << Previous Next >>